Lung cancer starts in the tissue in the lungs, usually in the cells that line the airways. It is the leading cause of cancer-related deaths worldwide, often associated with smoking but can also occur in non-smokers. Advances in early detection and combination therapies are improving outcomes for this aggressive disease.
Lifestyle habits and environmental exposures significantly influence the risk of lung cancer.
Main risk factor, especially in long-term or intensive smokers.
Passive exposure increases the risk, even for non-smokers.
Chronic exposure to particles and toxins contributes to the development of lung cancer.
Natural radioactive gas that is a major risk factor in poorly ventilated areas.
Symptoms often appear at advanced stages, making early detection crucial.
A persistent cough that is often worsened over time.
Rejection of blood when coughing, even in small quantities.
Pain or discomfort that worsens with deep breaths or coughing
Caused by airway obstruction or fluid accumulation.
The result of blood loss or the progression of advanced cancer.
Early detection significantly improves prognosis, especially for high-risk groups.
Recommended for current and former smokers aged 50 to 80.
Tissue sampling confirms the type and stage of the cancer.
Emerging technology that detects tumor DNA in the bloodstream.
Identify mutations like EGFR and ALK, guiding targeted therapies.
Lung cancer treatment is guided by the type of cancer (small cell or non-small cell), stage, and health status of the patient.
Lobectomy or pneumonectomy for tumors that are localized at an early stage.
Targets tumours that cannot be surgically removed
Platinum-based protocols for the systemic treatment of advanced cancers.
Checkpoint inhibitors like pembrolizumab improve survival in some patients.
EGFR inhibitors (e.g. gefitinib) for cancers with specific genetic mutations.
ALK inhibitors for ALK-positive tumors.